Kalyan Das

This study investigates the antiviral activity and mechanism of 4'-fluoroadenosine against viral and host polymerases, showing broad-spectrum inhibition and potential for drug development.

The paper shows that the Q226H mutation in H5N1 hemagglutinin allows binding to human-type a2-6 sialic acid receptors, suggesting a path towards human adaptation.

The paper investigates how dual-role regulators interact with the Sin3 complex using structural and functional analyses, revealing mechanisms for transcriptional crosstalk.

This study investigates remdesivir incorporation by SARS-CoV-2 RNA polymerase and the S759A resistance mechanism using enzymatic assays, mass spectrometry, and cryo-EM.

This study identifies mutations in influenza hemagglutinin that increase acid-stability and decrease cleavability, with implications for viral transmissibility and vaccine development.

This study determines cryo-EM structures of PhoP-dependent transcription complexes in Mtb to elucidate its dual role as activator and repressor in stress adaptation.

This paper identifies EPB-113, a guanidine-based inhibitor of coronavirus nsp15 endoribonuclease, which suppresses viral replication and selects for interferon-susceptible mutants.

The paper presents cryo-EM structures of human mitochondrial transcription initiation complexes, revealing mechanisms of start-site selection and slippage synthesis.

This paper identifies a non-enzymatic HDAC inhibitor with anti-tumor and anti-psychedelic effects, showing reduced gene modulation compared to enzymatic inhibitors.

This study reports crystal structures of ECF-sigma-factor-dependent transcription initiation complexes in Mycobacterium tuberculosis, revealing conserved interactions with RNAP and promoter DNA.

This paper reports the cryo-EM structure of Mycobacterium tuberculosis RNAP holoenzyme bound to fidaxomicin, revealing its unique binding site and mechanism of transcription inhibition.

This study reports crystal structures of Mycobacterium tuberculosis RNA polymerase with and without antituberculosis drugs, revealing a new class of inhibitors and their binding mechanisms.